News tagged with metastatic prostate cancer

A new study led by Vanderbilt University Medical Center investigators found new diagnoses of prostate cancer in the U.S. declined 28 percent in the year following the draft recommendation from the United States Preventive ...

A novel molecular imaging technology not only detects prostate cancer that has spread throughout the body, but also provides a potent and minimally invasive method of radiotherapy, reveal researchers at the 2015 Society of ...

A novel radionuclide drug tackles the challenge of prostate cancer imaging and takes a turn as a cancer-killing therapy for tumors in and out of the prostate, according to research presented during the 2015 Annual Meeting ...

You are a patient who has just been treated for a serious illness but neither you nor your doctor knows how likely it is that you—in comparison with other patients—will actually be helped by the treatment. This is often ...

Cleveland: Cleveland Clinic researchers have discovered for the first time that a metabolite of an FDA-approved drug for metastatic prostate cancer, abiraterone (Abi), has more anti-cancer properties than its precursor. The ...

New research led by the University of Warwick shows newly diagnosed advanced prostate cancer patients who received the chemotherapy drug docetaxel with standard hormone therapy lived ten months longer on average, compared ...

Chemotherapy can be very effective against small prostate tumors. Larger prostate tumors, however, accumulate cells that suppress the body's immune response, allowing the cancer to grow despite treatment. Researchers at the ...

(HealthDay)—More than one-quarter of patients with metastatic prostate cancer present with a synchronous second primary malignancy, according to a review published in the April issue of The Journal of Urology.

A common anti-fungal treatment has joined the ranks of drugs that may be suitable for use in treating cancer, according to research from the Repurposing Drugs in Oncology (ReDO) project published in ecancermedicalscience.

Enzalutamide (trade name: Xtandi) has been approved since December 2014 for men who have metastatic prostate cancer that is not susceptible to hormone-blocking therapy, who have no symptoms or only mild ones, and in whom ...